乙型肝炎核心抗原抗体与非乙型非丙型肝细胞癌治愈性治疗后生存的关系。

Relation between antibody to hepatitis B core antigen and survival after curative therapy for non-B non-C hepatocellular carcinoma.

机构信息

Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, 5-30 Fudegasaki-cho, Tennoji-ku, Osaka 543-0027, Japan.

出版信息

Anticancer Res. 2013 May;33(5):2211-9.

PMID:23645778

Abstract

BACKGROUND/AIM: We aimed to examine the relationship between antibodies to hepatitis B core antigen (anti-HBc) positivity and survival in patients with non-B non-C hepatocellular carcinoma (NBNC-HCC) who underwent curative treatment.

PATIENTS AND METHODS

A total of 260 patients with NBNC-HCC who underwent curative therapy were analyzed. They included 124 anti-HBc-positive patients (47.7%) and 136 anti-HBc-negative patients (52.3%). Overall survival (OS) and recurrence-free survival (RFS) rates were compared.

RESULTS

The 3-year cumulative OS rates were 75.9% in the anti-HBc-positive group and 82.3% in the anti-HBc-negative group (p=0.069). The corresponding RFS rates were 29.8% in the anti-HBc-positive group and 43.0% in the anti-HBc-negative group (p=0.001). Multivariate analyses identified anti-HBc positivity (p=0.006), aspartate aminotransferase ≥ 40 IU/l (p=0.037) and des-γ-carboxy prothrombin ≥ 100 mAU/ml (p=0.046) as significant adverse predictors were linked to RFS.

CONCLUSION

Anti-HBc positivity can be a useful predictor for recurrence in patients with NBNC-HCC after curative therapy.

摘要

背景/目的：我们旨在研究接受根治性治疗的非乙型肝炎非丙型肝炎肝细胞癌（NBNC-HCC）患者中，乙型肝炎核心抗原抗体（抗-HBc）阳性与生存之间的关系。

患者与方法

共分析了 260 例接受根治性治疗的 NBNC-HCC 患者。他们包括 124 例抗-HBc 阳性患者（47.7%）和 136 例抗-HBc 阴性患者（52.3%）。比较了总生存（OS）和无复发生存（RFS）率。

结果

抗-HBc 阳性组的 3 年累积 OS 率为 75.9%，抗-HBc 阴性组为 82.3%（p=0.069）。相应的 RFS 率在抗-HBc 阳性组为 29.8%，在抗-HBc 阴性组为 43.0%（p=0.001）。多因素分析确定抗-HBc 阳性（p=0.006）、天门冬氨酸氨基转移酶≥40IU/l（p=0.037）和去γ-羧基凝血酶原≥100mAU/ml（p=0.046）是与 RFS 相关的显著不良预测因素。